WhiteLab Genomics' USD 26 million Series B was first publicly reported on 5 October 2026, with its official announcement following on 6 October. AVP led the round. David Del Bourgo's Paris company applies AI to genomic medicine development, designing delivery-related biological assets and supporting drug developers working on next-generation treatments. Its investment story combines computational tools with the specific needs of a life-sciences development programme. The financing backs a team working on how genomic medicines can be developed and delivered. The announcement date reflects the earliest public coverage, while the official release provides confirmation of the round and its leadership.
WhiteLab Genomics raises USD 26m Series B
AVP leads funding for AI-designed genomic medicine assets

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


